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Estimating influenza vaccine effectiveness (IVE) early in the season 
helps measuring the consequences of a mismatch between the 
vaccine and the circulating strain and guiding alternative or 
complementary interventions. The European Centre for Disease 
Prevention and Control is funding a project to develop pilot studies 
to monitor IVE in the Member States (MS) of the European Union 
and European Economic Area (EU/EEA) during seasonal and 
pandemic influenza. To identify key methodological and practical 
issues in developing protocols for pilot studies, we conducted a 
survey among EU/EEA MS, a literature review on IVE methods, 
and consultations of experts. The survey and literature review 
highlighted the variety of the data sources used to estimate IVE 
and the difficulty to interpret data on IVE, which varies with age, 
risk group, outcome specificity and virus-vaccine mismatch. We 
also found that negative and positive confounding can bias IVE. 
The experts consultations lead to the following recommendations: 
to measure IVE in the same population in various seasons; to 
control for positive/negative confounding (including pre- and 
post-influenza season IVE estimates); and to include laboratory 
confirmation as outcome in various study designs. In the 2008-9 
influenza season, two cohort studies using general practitioners’ 
databases and six case control studies will be piloted in EU/EEA 
MS and will adhere to the above recommendations. The pilot 
studies will be the basis for the development of robust methods 
to monitor IVE in EU/EEA MS. 
Background
Because influenza viruses are constantly changing and vaccines 
are reformulated every year, the influenza vaccine effectiveness 
(IVE) estimates from previous years cannot be used to estimate IVE 
in the subsequent years. Having annual IVE estimates at European 
level available as soon as possible after the start of a seasonal 
influenza epidemic or pandemic and monitoring it along the course 
of the epidemic/pandemic is essential in order to: 
• decide on recommendations for the use of the vaccine by 
specific age and risk groups, 
• target complementary or alternative public health measures 
(e.g. antivirals) to population segments in which the vaccine is 
less effective, 
• estimate more precisely the impact of current vaccination 
strategies on the burden of disease with a view to supporting 
vaccination campaigns, 
• provide some quantification to the current virological system 
of comparing antigenic matches of vaccine and circulating 
viruses, 
• trigger further investigations on seasonal and pandemic vaccines 
(improving their composition, use of adjuvants, need for booster 
doses), 
• better manage and respond to eports of vaccine failures 
(especially during a pandemic), 
• counterbalance the reports of adverse events following 
immunisation by providing a basis for adequate risk management 
and cost-effectiveness analysis.
In addition, in order to be able to measure IVE for the pandemic 
vaccine it is necessary to develop already now a robust method that 
provides early estimates of IVE.
As the vaccine is recommended for risk groups, clinical trials 
to estimate IVE in Europe would not be ethical. Only observational 
studies can be considered when trying to obtain IVE estimates 
early in the season [1]. It is therefore necessary to define which 
observational study designs can be adopted in the Member States 
(MS) of the European Union and European Economic Area (EU/
EEA) that would provide IVE estimates during an ongoing influenza 
season and allow monitoring it through consecutive seasons. These 
methods need to take into account the specific situation of each 
MS in terms of resources and available data.  
The European Centre for Disease Prevention and Control (ECDC) 
is funding the development and piloting of study protocols for 
monitoring IVE in EU/EEA MS in the context of seasonal and 
pandemic influenza. A consortium of 18 European public health 
institutes coordinated by EpiConcept is carrying out this project. 
The first phase (January-July 2008) consisted of the development 
of protocols for the pilot studies. To identify key methodological 
and practical issues to be considered in the study protocols, we 
conducted a survey among EU/EEA MS, a literature review on 
methods used to estimate IVE, and three consultations of experts. 
These three approaches are described in the following sections of 
this article.
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Survey 
Survey methods
We carried out a survey among EU/EEA Member States to 
identify, in each MS, observational IVE studies and available data 
sources that could be used for real-time IVE studies. 
We contacted 29 experts from 29 EU/EEA MS involved in 
influenza surveillance. The experts were the representatives of the 
institutions included in the consortium and, for MS not participating 
in the consortium, the epidemiologist focal point of the European 
Influenza Surveillance Scheme (EISS) or the gatekeeper of the 
Vaccine European New Integrated Collaboration Effort (VENICE). 
The experts were given the options either to provide information 
through a self-completed questionnaire or during a telephone or 
face to face interview. In addition, we reviewed available reports 
from EISS and VENICE, web pages from European institutions 
involved in influenza surveillance and articles on IVE studies 
conducted in EU/EEA MS. 
We collected data on IVE studies conducted in the MS, available 
data sources for case identification (identification of influenza 
cases, death registries, hospital registries, general practitioners’ 
(GP) databases, other) and for documenting influenza vaccination 
status, as well as potential interest in conducting a pilot study 
during the season 2008-9.
Survey results 
Among the 29 MS we contacted, 24 (83%) accepted to 
participate in the survey. In four MS, we interviewed the experts 
face to face, in 12 by telephone and in eight MS, the experts self-
completed the questionnaire we sent them. 
Of the participating 24 MS, ten had conducted IVE studies in 
the past. We identified 43 published articles reporting results of 
case control studies (12 articles), of cohort studies (28 articles) 
and of studies using a screening method (three articles).  Additional 
details on the studies including data sources and study outcomes 
are reported in the Table. A complete survey report is also planned 
to be published on the ECDC website. 
In most of these studies, the study population and data sources 
had been identified through health delivery services. In the Czech 
Republic, Italy and Portugal, other data sources had been used for 
IVE studies as reported in the Table. 
Computerised databases
Malta, Norway and Sweden have population registries including 
an individual unique identifier which allows linking existing 
databases (e.g. death registers, in-patient registers, vaccination 
registers if available). The linkage of the various databases is not 
immediate and an ethical or a personal protection approval is 
needed.
In Finland, France, Ireland, the Netherlands, Norway, and the 
United Kingdom (UK), various GP networks have computerised 
databases. Computerised GP databases are also available in some 
regions in Spain and in some counties in Sweden. 
Computerised GP databases allow evaluating various outcomes: 
influenza-like illness (ILI)/acute respiratory infections (ARI), death, 
hospitalisation, vaccine status and some confounding factors (e.g. 
co-morbidities). However, certain issues need to be considered 
when using computerised databases for IVE studies, such as the 
representativeness, completeness, timeliness and quality of the 
data. For some of the databases, ad hoc studies may be necessary 
to further evaluate data quality. 
Computerised databases have been used in the Netherlands, 
Spain, Sweden and the UK to conduct IVE cohort studies. They can 
provide rapid estimates for some outcomes (e.g. ARI/ILI) and more 
solid estimates at the end of the season (e.g. estimates adjusted for 
confounding factors, estimates for severe clinical outcomes).  
Sentinel surveillance
In all 24 responding MS, the main source to identify clinical 
cases of influenza on a real-time basis was the virological or 
epidemiological sentinel influenza surveillance system. Case 
definitions vary from MS to MS but most sentinel networks report 
cases of ILI symptoms or ARI [44]. 
Laboratory confirmation of influenza cases is usually done in a 
subset of patients consulting the sentinel practitioners. In most MS, 
the decision of which patients to collect laboratory specimens from 
is based on clinical criteria. Thus, patients with laboratory tests are 
not a representative sample of all patients consulting a GP because 
of influenza symptoms [45]. In Denmark and France, the patients 
to be sampled are selected in a systematic way. Following EISS 
recommendations, laboratory request forms include the patients´ 
vaccination status. 
Sentinel surveillance systems have been used to conduct 
case control studies of IVE in Denmark, France, Germany, the 
Netherlands, and the UK (Table).
Hospitalisation discharge databases 
In most MS, cases with severe clinical influenza outcome 
(hospitalisations, deaths) are not identified in real time. 
Hospitalisation discharge databases are available with delays 
varying from three months to two years. In France, hospitals report 
on a daily basis to the Institut de Veille Sanitaire individual data 
from in-patients and out-patients consulting emergency rooms. 
Various MS have developed or are developing real-time mortality 
monitoring [46]. Mortality has not yet been used in Europe to 
estimate real-time IVE. 
Influenza vaccination status 
Sources to document influenza vaccination status include 
medical records, computerised medical records, immunisation 
registries, surveys, and pharmaceutical data [47]. Vaccination 
registries allowing the extraction of real-time vaccination status 
are currently available at regional level in Finland, in some counties 
in Sweden and in some regions in Spain. In 2008-9, Spain plans to 
estimate real-time vaccination coverage using vaccination coverage 
reported by the sentinel practitioners. 
Literature review
In addition to the survey described above, a literature review 
was conducted to identify the key elements to be considered in 
the design of the pilot studies. In particular, we focused on factors 
affecting IVE estimates and on methods described to control them. 
In the following paragraphs, we summarise factors that will have 
an influence on the choices made when developing the pilot study 
protocols: outcomes and confounding factors. 
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T a b l e
Influenza vaccine effectiveness studies conducted in EU/EEA Member States, by study design and country
Country Reference Data source Outcome
Cohort Studies
Czech Republic
Chlíbek 2002 [2] Mail questionnaire to volunteers Influenza-like illness
Berran 2003 [3] Medical records employees Skoda Auto factory Influenza-like illness
Italy
Comeri 1995 [4] Questionnaire to a sample of the elderly population in one city Clinical influenza
Consonni 2004 [5] Phone interviews, ambulatory patients Influenza-like illness, acute respiratory infection
Pregliasco 2002 [6] Interviews, medical records geriatric units Acute respiratory infection, hospitalisation
Rizutto 2006 [7] Interviews volunteer participants from Ministry of Health Influenza-like illness
Landi 2003 [8], Landi 2006 [9] Minimum data Set for home care, Italian ‘Silver Network’ home careproject Death (2003), hospitalisation (2006)
The Netherlands
Smits 2002 [10] Computerised primary care practices Low respiratory tract infection, otitis media
Tacken 2004 [11] GP database Primary care contact rate during influenza epidemics
Voordow 2003 [12], 2006 [13] GP database Influenza, pneumonia, death, low respiratory tract infection, hospitalisation for pneumonia
Portugal 2006-7, 2007-8 (unpublished data) Pharmacies, voluntary recruiters Laboratory-confirmed influenza
Spain
Castilla, 2006 [14] Sentinel GPs Clinical influenza
Gené Badía 1991 [15] Records from five health centres, hospital, death register
Death, all hospitalisations, hospitalisations for 
respiratory diseases
López Hernández 1994 [16] Records from one health centre, hospital records, death register Hospitalisation, death
Salleras, 2006 [17] Questionnaires in clinics Acute febrile illness, influenza-like illness, laboratory-confirmed influenza
Vila-Córcoles 2007 [18] GP electronic files, demographic database, death registry Death
Sweden Christenson 2001 [19], Christenson 2004 [20],  Orktvist 2007 [21]
Population register, vaccination database, 
discharge diagnosis database
Influenza hospitalisation, hospitalisation for 
pneumonia
UK
Fleming 1995 [22] GP database Death, death or severe respiratory illness, death or any respiratory illness without further specification
Armstrong 2004 [23] GPs, Office for National Statistics Death attributable to influenza
Mangtani 2004 [24] General Practice Research Database Hospitalisation for respiratory disease, death from respiratory disease
Cohort studies during outbreak investigations
France Aymard 1979 [25] Geriatric hospital Disease, death
Italy Caminiti 1994 [26] Medical charts, hospital records, death certificates 
Influenza-like illness, hospitalisation for influenza-
like illness, hospitalisation for all respiratory 
illness, death from respiratory illness
UK
Arroyo 1984 [27] One nursing home Influenza-like illness, pneumonia, death from respiratory disease
Mukerjee 1994 [28] 14 nursing homes Upper respiratory tract infection
Nicholls 2004 [29] Influenza-like illness
Case control studies
Denmark Mazick 2006 [30] GP surveillance network Influenza-like illness laboratory-confirmed
France
Carrat 1998 [31] GP practices Acute respiratory infection, influenza-like illness laboratory-confirmed
Lavallée 2002 [32] Medical records of hospitalised cases, interviews Hospitalisation for acute respiratory infection and hospitalisation for brain infarction
Germany
Grau 2005 [33] Hospital records, patient interviews Hospitalisation for ischaemic or haemorrhagic stroke / transient ischaemic attack
Uphoff 2006 [34]
Sentinel GPs
cases: influenza-like illness influenza-positive
controls: influenza-like illness influenza-negative 
Influenza-like illness laboratory-confirmed
Italy Crocetti 2001 [35] Discharge diagnoses, mailed questionnaire, telephone interviews Hospitalisation for pneumonia or influenza
The Netherlands
Hak 2002 [36] Administrative and medical databases from a health plan
GP visit and hospitalisations for acute respiratory 
disease and cardiovascular disease
RIVM 2006-7
(unpublished data)
Sentinel GPs 
cases: influenza-like illness influenza-positive
controls: influenza-like illness influenza-negative
Influenza-like illness laboratory-confirmed
Spain Puig-Barberá 1997 [37], 2004 [38], 2007 [39] Hospital emergency logs and records 
Hospitalisation for acute coronary syndrome, 
hospitalisation for cerebrovascular accident, 
hospitalisation for pneumonia
UK
Ahmed 1995 [40] Death certificates, GP records Certified influenza death
Jordan 2007 [41] GP practice registries and hospital discharge registries Hospitalisation for acute respiratory infection
UK (Scotland)
Health Protection Scotland, 2005-6 
and 2006-7
(unpublished data)
Sentinel GPs 
cases: influenza-like illness influenza-positive
controls: influenza-like illness influenza-negative
Influenza-like illness laboratory-confirmed
Screening
France
Carrat 1998 [42] Cases: sentinel GPs;vaccine coverage: national health survey Influenza-like illness 
Legrand 2006[43] Cases: sentinel GPs;vaccine coverage: national health survey Influenza-like illness 
Germany Uphoff 2006[34] Cases: sentinel GPs;vaccine coverage: national health survey Influenza-like illness laboratory-confirmed
Spain Instituto de Salud Carlos III (unpublished data)
Cases: sentinel GPs;
vaccine coverage: national health survey Influenza-like illness
GP: General Practitioner
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Literature review methods
To identify relevant papers, we searched the Cochrane database 
and consulted Cochrane reviews on influenza vaccine effectiveness 
[48,49]. Additionally, we reviewed the Health Technology 
Assessment report “Systematic review and economic decision 
modelling for the prevention and treatment of influenza A and B” 
[50]. We also included a recent Sanofi Pasteur-MSD review [51]. 
Finally, we also reviewed references from each of the selected 
articles. 
We selected studies providing IVE estimates. We also included 
studies addressing methodological aspects of IVE estimates and 
certain studies addressing the methodology of VE measurements 
for infectious diseases.
Literature review results
Overall, we reviewed 284 scientific articles and of them selected 
93 descriptive observational studies (34 cohort studies, 26 outbreak 
investigations, 31 case control studies and two studies using the 
screening method). In addition we consulted 23 articles focusing 
on methodological issues.
Clinical outcome
The main clinical outcomes reported in the literature were 
hospitalisations for all or specific causes (e.g. pneumonia and 
influenza), deaths from all or specific causes (e.g. pneumonia and 
influenza), ILI, ARI and laboratory-confirmed cases of influenza.
IVE studies using non-specific clinical outcomes will include as 
cases individuals with clinical symptoms unrelated to influenza, 
leading to an underestimation of the IVE [52,53]. The influenza 
case definition combined with laboratory confirmation results has 
the highest specificity for influenza, and  laboratory confirmation is 
therefore essential to estimate the true IVE [54]. Due to the costs 
involved, some authors have suggested to perform laboratory tests 
only in a small proportion of the study participants (validation set) 
[55].
Confounding factors
Comparing the crude IVE estimates and the IVE estimates 
adjusted for confounding factors reported in the literature provides 
an overview of the magnitude of confounding in IVE studies. We 
found a difference in percentage between crude and adjusted IVE 
in case control studies (Figure 1) and cohort studies (Figure 2) that 
ranged from -220% to 21%.
The list of potential confounding factors reported in the literature 
is very long (Box).
The main confounding factors discussed in the literature are 
factors resulting either in an underestimation of the IVE (negative 
confounding) or in an overestimation of the IVE (positive confounding 
factors). Negative confounding is the result of ‘confounding by 
indication’: Individuals that are at high risk of influenza are more 
likely to be vaccinated than individuals that are at low risk, and 
consequently, IVE is underestimated. Positive confounding is the 
consequence of healthier individuals being more conscious about 
their health, more motivated to accept vaccination and therefore 
more likely to be vaccinated than unhealthier individuals. An 
alternative explanation for positive confounding is the fact that 
critically ill patients are not offered (or refuse) to be vaccinated. 
Therefore, vaccinated individuals have a better baseline health 
status than the unvaccinated group leading to an overestimation 
of the IVE (‘healthy vaccinee’ effect). 
Different alternatives have been proposed to adjust for the 
‘healthy vaccinee’ and ‘confounding by indication’ effects.  Some 
authors restricted the study population to groups that were more 
homogeneous with regard to the potential confounding factor. 
Others stratified the results according to risk groups. A majority 
of the studies reviewed included the potential confounders as 
covariates in a regression model. Some authors controlled for 
confounding using propensity scores, the conditional probability 
of being vaccinated given observed covariates [11,18,39,56-58]. 
They are used to group individuals at levels of the propensity score 
or as a covariate in the regression model. 
Comparison with non-influenza season data
Some authors considered those adjustment methods insufficient 
to adjust for the ‘healthy vaccinee’ effect and suggest that residual 
confounding may persist. They proposed to compare the IVE 
estimates in the influenza season with estimates from periods with 
B o x
List of potential confounding factors in influenza vaccine 
effectiveness studies reported in the literature
Age•	
Allergy to egg protein•	
Asthma•	
Diabetes mellitus and other endocrine diseases•	
Disease severity•	
Education level•	
Functional status•	
Former Influenza vaccination•	
Former Pneumococcal vaccination•	
Health medical organisation•	
Health-related behaviours•	
Heart diseases•	
House heating•	
Immunosuppression including haematopoietic malignant diseases and •	
steroid and immunosuppressive treatment
Index case in the family •	
Length of hospital stay•	
Level of social interaction•	
Lifestyle factors•	
Living together with grandchildren•	
Malignant disorders•	
Marital status•	
Medication prescribed and number of repeat prescriptions•	
Musculoskeletal and connective tissue diseases•	
Neurological diseases (including dementia, Parkinson’s disease and •	
cerebrovascular diseases)
Number of co-habitants•	
Number of hospital admissions and out-patient visits •	
Other pulmonary diseases•	
Physical activity•	
Place of residence: nursing and residential care homes; non-institutional•	
Pre-school attendance•	
Preventive care practices•	
Propensity score•	
Renal diseases•	
Sex•	
Smoking•	
Socio-economic status•	
Type of medical coverage•	
Underlying chronic conditions •	
Vaccination of caregiver•	
Washing hands and gargling•	
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F i g u r e  1
Difference between crude and adjusted influenza vaccine effectiveness estimated in case control studies, by study outcome
ARD, acute respiratory disease including acute bronchitis or exacerbations of chronic lung disease, influenza, pneumonia, and acute otitis media;
CVD, cerebrovascular disease including myocardial infarction, stroke, and heart failure;
GP, general practitioner; 
ILI: influenza-like illness
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F i g u r e  2
Difference between crude and adjusted influenza vaccine effectiveness estimated in cohort studies, by study outcome
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no influenza. The rationale behind this is that the vaccine should 
not have an effect in non-influenza seasons. 
Several studies using this approach compared IVE during and 
after the influenza season. Most of the results showed a lower IVE 
after the season suggesting that there was no positive confounding 
[21,24,59-61]. Other authors, however, found a greater reduction 
in the risk of death and pneumonia hospitalisation in the period 
before the influenza season compared to the time during the 
influenza season, suggesting positive confounding [62]. They argue 
that studies that did not find an association between vaccine and 
disease outcome (low IVE) after the influenza season had assumed 
the difference in underlying characteristics to be constant over 
time. They suggest that the differences between vaccinated and 
unvaccinated individuals may diminish over time and the data 
should therefore be compared not only with the post-influenza 
season, but also with the pre-influenza season. 
Expert consultations
During the first phase of the project, we organised several 
workshops for experts participating in the consortium and additional 
invited influenza experts. 
The first workshop was held in April 2008. The aim was to 
present and discuss the results of the literature review and survey 
as described above and to consider the feasibility of the various 
observational methods to estimate real-time IVE at EU/EEA level. 
The participants included 25 experts from institutions participating 
in the consortium, four external influenza experts (London School 
of Hygiene and Tropical Medicine, Instituto de Salud Pública de 
Castellón, Sanofi Pasteur MSD, United States-Centers for Disease 
Control and Prevention Influenza division), four staff members 
from the ECDC Scientific Advice Unit and two EpiConcept 
epidemiologists. 
The participants worked in three groups to discuss cohort studies, 
case control studies, and screening method studies. For each study 
design, the groups made recommendations to be considered in the 
development of generic protocols for the pilot studies. The experts’ 
recommendations were to determine IVE in various population 
subgroups, to control for positive and negative confounding and 
to use laboratory-confirmed influenza as outcome. The group 
recommended measuring IVE in a homogenous population for a 
period of several years, using the same design each year.  The 
participating MS and ECDC expressed their interest in supporting 
this project in the long term. 
Following the first workshop, we developed two generic protocols 
(see below) for case control and cohort studies to be adapted to 
the situation of each MS. 
The second set of consultations was held in June 2008 with the 
MS that were interested in conducting pilot studies in the season 
2008-9. The objective was to further discuss methodological issues 
related to the two generic protocols for measuring IVE. Specific 
sessions were held for each study design. 
The group agreed that, during the first season of the pilot phase, 
2008-9, the following study designs were to be considered: 
• Case-control studies based on influenza sentinel surveillance 
systems with laboratory-confirmed influenza-positive ILI as 
cases and influenza-negative ILI as controls. 
• Prospective cohort studies using computerised databases and 
providing IVE estimates for different periods (pre-/during/post-
influenza season). At least a subset of the cases would be 
laboratory-confirmed. 
Conclusion
The survey showed that data sources to conduct IVE studies 
vary from MS to MS and in some MS from region to region. 
Computerised databases are available in few countries and, where 
available, are a good basis for cohort studies as they include large 
populations. Sentinel GP networks are present in all 24 EU/EEA MS 
that participated in the survey; they include laboratory confirmation 
of influenza cases and data on vaccination status for a subset of 
the population. 
The literature review underlined the difficulty to interpret IVE 
estimates. IVE estimates vary with age, risk group and the specificity 
of the disease outcome. In addition, IVE estimates can be heavily 
biased by positive or negative confounding. 
The expert consultations led to specific recommendations to 
be applied in the next phase of the project. Eight studies will be 
piloted in the 2008-9 season: two cohort studies, one case control 
nested in one of the cohorts, and five case control studies. 
The two cohort studies will be conducted in England and 
Scotland, and in the Comunidad Autónoma de Navarra, Spain, using 
GP databases. These two studies will provide IVE for the pre- and 
post-influenza season and will allow to further analyse confounding 
factors included in the GP database. IVE will be estimated against 
ILI (both studies), all respiratory infections (England and Scotland), 
pneumonia and influenza hospitalisations (Navarra), all respiratory 
hospitalisations (Navarra), and all deaths (Navarra). In Navarra, a 
subset of patients will be laboratory-confirmed. 
A case control study with laboratory-confirmed outcome will be 
nested in the England and Scotland cohort. 
In addition, five case control studies among the elderly population 
will be conducted during the influenza season in Denmark, Hungary, 
Portugal, Romania and Spain. The vaccine status of ILI cases that 
are laboratory-confirmed for influenza will be compared to various 
sets of controls including influenza-negative ILI cases, controls from 
GP patients and controls from GP catchment areas. 
The five studies will use the recommended European 
Commission case definition for ILI and a common definition for 
potential confounding factors such as functional status, underlying 
diseases, severity, smoking, previous influenza vaccination and 
pneumococcal vaccination. Therefore, the possibility of pooling the 
results from those five studies to have a multicentre IVE estimate 
will be explored.
Results of the 2008-9 pilot studies will be presented in an 
expert meeting in June 2009. Based on those results, amendments 
to the protocols will be proposed and implemented in the next 
round of pilot studies in the same eight countries in the season 
2009-10. Subject to available resources, at least two additional 
pilot studies will start in 2009. 
The results of the pilot studies will guide the establishment of a 
system capable to provide and share rapid and reliable information 
on IVE on an annual basis. The intention is for this information to be 
integrated as an essential part of the routine influenza surveillance 
outputs/data. In order to achieve the successful inclusion of IVE 
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data in regular influenza surveillance, sustained commitment from 
all partners as well as secured funding is fundamental. 
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